These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2076592)

  • 21. In vitro antibacterial activity of cefotetan against Bacteroides fragilis group clinical isolates.
    Menozzi M; Avanzini P; Lecchini R; Bigi M; Chezzi C
    Chemioterapia; 1987 Jun; 6(2 Suppl):88-91. PubMed ID: 3509541
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison of susceptibility results of the Bacteroides fragilis group and other anaerobes by traditional MIC results and statistical methods.
    Aldridge KE; Johnson WD
    J Antimicrob Chemother; 1997 Mar; 39(3):319-24. PubMed ID: 9096180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Activity of cefotetan against anaerobic bacteria].
    Sedallian A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):643-4. PubMed ID: 2877431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of antibiotic activities by using serum bactericidal activity over time.
    Guglielmo BJ; Rodondi LC
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1511-4. PubMed ID: 3056237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-antibiotic effect in Bacteroides fragilis group.
    Siverhus DJ; Edmiston CE; Clausz JC; Goheen MP
    Ann Clin Lab Sci; 1988; 18(4):326-36. PubMed ID: 3165611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan.
    Cruciani M; Navarra A; Bono L; Concia E
    Chemioterapia; 1988 Aug; 7(4):261-3. PubMed ID: 3180306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased resistance to cefoxitin and cefotetan among Bacteroides fragilis isolates from abdominal sources in patients undergoing surgery.
    Ehrenkranz NJ; Alfonso B
    Clin Infect Dis; 1993 Dec; 17(6):1080-2. PubMed ID: 8110948
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibiotic- and method-dependent variation in susceptibility testing results of Bacteroides fragilis group isolates.
    Aldridge KE; Sanders CV
    J Clin Microbiol; 1987 Dec; 25(12):2317-21. PubMed ID: 3480894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.
    O'Keefe JP; Venezio FR; DiVincenzo CA; Shatzer KL
    Antimicrob Agents Chemother; 1987 Dec; 31(12):2002-4. PubMed ID: 3439807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
    Downes J; Andrew JH
    Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
    Canawati HN
    Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
    Turgeon P; Turgeon V; Gourdeau M; Dubois J; Lamothe F
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2276-9. PubMed ID: 7840557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    J Clin Microbiol; 1987 Apr; 25(4):645-9. PubMed ID: 3571474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem.
    Andrew JH; Greenwood D
    J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    Chemioterapia; 1988 Aug; 7(4):264-6. PubMed ID: 2902937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of cefoxitin vs. cefotetan against clinical isolates of Bacteroides and Prevotella species.
    Grossmeyer TJ; Farmer SG
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S353-6. PubMed ID: 8324146
    [No Abstract]   [Full Text] [Related]  

  • 39. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.
    Aldridge KE; Wexler HM; Sanders CV; Finegold SM
    Antimicrob Agents Chemother; 1990 Jan; 34(1):179-81. PubMed ID: 2327757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.